InvestSMART

Oncosil Medical Limited (ASX: OSL) - Announcements

Current share price for OSL : $1.210 0.05 (3.97%)+

ASX company news and announcements for Oncosil Medical Limited (OSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Oncosil Medical Limited (OSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Oncosil Medical Limited (OSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Oncosil Medical Limited (OSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$37 OncoSil Appoints Rachel Duggan as EMEA Sales Director 29 Oct 2024 9:35AM $0.011 $1.210 risen by 10,900%
$37 Proposed issue of securities - OSL 28 Oct 2024 9:53AM $0.013 $1.210 risen by 9,207.69%
$37 Capital Raise Presentation 28 Oct 2024 9:37AM $0.013 $1.210 risen by 9,207.69%
$37 Proposed issue of securities - OSL 28 Oct 2024 9:21AM $0.013 $1.210 risen by 9,207.69%
$37 Proposed issue of securities - OSL 28 Oct 2024 9:05AM $0.013 $1.210 risen by 9,207.69%
$37 OSL completes $7 M Placement and announces $1 M SPP 28 Oct 2024 9:05AM $0.013 $1.210 risen by 9,207.69%
$37 G-BA Approval received for OncoSil Device 24 Oct 2024 9:56AM $0.013 $1.210 risen by 9,207.69%
$37 Trading Halt 24 Oct 2024 8:42AM $0.013 $1.210 risen by 9,207.69%
$37 Notice of Annual General Meeting 22 Oct 2024 8:36AM $0.012 $1.210 risen by 9,983.33%
$37 OncoSil Medical Limited Receives UKCA Renewal Certificates 21 Oct 2024 8:29AM $0.012 $1.210 risen by 9,983.33%
$37 OncoSil signs distribution agreement with Al Zahrawi Medical 7 Oct 2024 9:50AM $0.014 $1.210 risen by 8,542.86%
$37 Application for quotation of securities - OSL 2 Oct 2024 4:59PM $0.013 $1.210 risen by 9,207.69%
$37 Corporate Governance Statement and Appendix 4G 30 Sep 2024 7:05PM $0.014 $1.210 risen by 8,542.86%
$37 Annual Report Differences to Appendix 4E 30 Sep 2024 7:04PM $0.014 $1.210 risen by 8,542.86%
$37 Annual Report 30 Sep 2024 6:54PM $0.014 $1.210 risen by 8,542.86%
$37 Peter Hall elects not to join OncoSil Board 30 Sep 2024 9:19AM $0.015 $1.210 risen by 7,966.67%
$37 50% Recruitment in TRIPP-FFX and PANCOSIL Clinical Trials 26 Sep 2024 9:05AM $0.013 $1.210 risen by 9,207.69%
$37 Application for quotation of securities - OSL 18 Sep 2024 5:31PM $0.014 $1.210 risen by 8,862.96%
$37 Results of Meeting 18 Sep 2024 12:26PM $0.014 $1.210 risen by 8,862.96%
$37 Comparative Analysis Indicates Benefits from OncoSil 18 Sep 2024 8:54AM $0.014 $1.210 risen by 8,542.86%
$37 Strong Market Penetration with 30th OncoSil Treatment 13 Sep 2024 9:39AM $0.013 $1.210 risen by 9,207.69%
$37 Appointment of Peter Hall as Non-Executive Director 30 Aug 2024 3:00PM $0.010 $1.210 risen by 12,000%
$37 Appendix 4E Preliminary Financial Report 30 Aug 2024 8:59AM $0.011 $1.210 risen by 11,423.81%
$37 Notice of Extraordinary General Meeting/Proxy Form 20 Aug 2024 8:25AM $0.012 $1.210 risen by 9,983.33%
$37 Significant Growth in Commercial Treatment Sales in Q4 FY24 15 Aug 2024 10:13AM $0.010 $1.210 risen by 12,000%

201 - 225 of 791 results

Page 9 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.